Evidence map›Paper›PMID 38193650›Full record

ArticleInternational journal of urology : official journal of the Japanese Urological Association2024

Clinicopathological characteristics of adrenocortical carcinoma in the Kyushu-Okinawa area of Japan.

Shotaro Nakanishi, Yumi Fukushima, Junichi Inokuchi, Tomoaki Hakariya, Hiroaki Kakinoki, Hideki Enokida, Katsuaki Chikui, Hirofumi Matsuoka, Toshitaka Shin, Shoichiro Mukai and 9 more

Open access · hybridAbstract readMulticenter Study
In one paragraph

Article in International journal of urology : official journal of the Japanese Urological Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Prognostic Factors Among Patients with Non-metastatic Adrenocortical Carcinoma.International journal of endocrinology and metabolism · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 11 institutions in 1 country.

Shotaro NakanishiDepartment of Urology, Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan.ORCID 0000-0002-0117-9490
Yumi FukushimaDepartment of Urology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Junichi InokuchiDepartment of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Tomoaki HakariyaDepartment of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Hiroaki KakinokiDepartment of Urology, Faculty of Medicine, Saga University, Saga, Japan.
Hideki EnokidaDepartment of Urology, Faculty of Medicine, Kagoshima University, Kagoshima, Japan.
Katsuaki ChikuiDepartment of Urology, Kurume University School of Medicine, Kurume, Japan.
Hirofumi MatsuokaDepartment of Urology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.ORCID 0000-0002-8799-7039
Toshitaka ShinDepartment of Urology, Faculty of Medicine, Oita University, Yufu-Shi, Japan.ORCID 0000-0001-7015-4281
Shoichiro MukaiDepartment of Urology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.ORCID 0000-0002-1678-8619
Tomomi KambaDepartment of Urology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Masatoshi EtoDepartment of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Ryoichi ImamuraDepartment of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Mitsuru NoguchiDepartment of Urology, Faculty of Medicine, Saga University, Saga, Japan.
Tsukasa IgawaDepartment of Urology, Kurume University School of Medicine, Kurume, Japan.
Nobuhiro HagaDepartment of Urology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Toshiyuki KamotoDepartment of Urology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.ORCID 0000-0002-7728-289X
Naohiro FujimotoDepartment of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.ORCID 0000-0002-5256-6415
Seiichi SaitoDepartment of Urology, Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan.
Fukuoka University · JPKumamoto University · JPKurume University · JPKyushu University · JPNagasaki University · JPSaga University · JPUniversity of Miyazaki · JPUniversity of the Ryukyus · JPKagoshima University · JPOita University · JPUniversity of Occupational and Environmental Health Japan · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveAdrenocortical carcinoma is a rare condition, with limited comprehensive reports from Japan. This study aimed to review Japan's data on adrenocortical carcinoma by assessing information from 46 patients-with adrenocortical carcinoma across 10 Japanese university hospitals.

methodsWe conducted a retrospective multi-institutional analysis of the clinical characteristics of adrenocortical carcinoma in Japan. We evaluated data from 46 patients across 10 university hospitals over 10 years and analyzed the relationship between clinicopathological characteristics and overall survival.

resultsFive- and 10-year overall survival rates were 59% and 53%, respectively. Overall survival was significantly different among the tumor-node-metastasis system for adrenocortical carcinoma of the American Joint Committee on Cancer/International Union Against Cancer, with the worst prognosis in stage IV (p = 0.0044). In our cohort, neither the Weiss score nor the Ki-67 proliferation index correlated with overall survival. Adjuvant treatment did not yield improved overall survival, whereas resection of the primary tumor in stage IV disease was significantly associated with improved overall survival (p = 0.0262). Out of the cases evaluated for plasma hormones, plasma cortisol, aldosterone, testosterone, and DHEA-S levels were measured at 23%, 42%, 29%, and 62%, respectively, demonstrating higher levels than the upper normal limits.

conclusionPatients with stage IV adrenocortical carcinoma had a poor prognosis; however, resection of the primary tumor in stage IV disease was associated with prolonged survival. The results of this study are expected to contribute to future treatment of adrenocortical carcinoma in Japan.

Indexed as

Adrenal Cortex NeoplasmsAdrenocortical CarcinomaAdolescentAdultAgedAged, 80 and overAldosteroneDehydroepiandrosterone SulfateFemaleHumansHydrocortisoneJapanMaleMiddle AgedNeoplasm StagingPrognosisAldosteroneDehydroepiandrosterone SulfateHydrocortisoneTestosteroneadjuvant treatmentadrenocortical carcinomasurgical role

Identifiers

PMID38193650
PMCPMC11524083
OpenAlexW4390758079

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.